Research analyst, medium-term horizon, biotech, small-cap

Pozen, Inc.: Buy This Biotech For Growth And Income

On May 8, 2014, Pozen, Inc. (NASDAQ:POZN) reported financial results for the first quarter ended March 31, 2014. Total revenues in the fourth quarter were $7.5 million, comprised of $4.5 million in royalties on $34 million in sales of Vimovo at Horizon Pharma (NASDAQ:HZNP) in the U.S. and $19 million in sales at AstraZeneca (NYSE:AZN) outside the U.S., and $3.0 million in licensing revenue relating to amortization of the $15 million upfront payment from Sanofi U.S. on the PA licensing agreement in September 2013. Revenues for quarter were up 703% from the first quarter 2013 and absolutely crushed our expectations of $5.0 million - with all the upside coming from higher royalties on Vimovo....

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details